12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trametinib regulatory update

GlaxoSmithKline said FDA extended the PDUFA date by 3 months for an NDA for trametinib to treat patients with unresectable or metastatic melanoma with BRAF V600 mutations as detected by an FDA-approved test. The new date is Sept. 3; the original date was...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >